Additional insights into how cancer cells use PARP1 enzyme to resist current therapies may also point to the next generation of cancer drugs
In the cells of humans and other organisms, only a subset of genes are active at any given time, depending largely on the stage of life and the particular duties of the cell. Cells use different molecular mechanisms to orchestrate the activation and deactivation of genes as needed. One central mechanism is an intricate DNA packaging system that either shields genes from activation or exposes them for use.
In this system, the DNA strand, with its genes, is coiled around molecules known as histones, which themselves are assembled into larger entities called nucleosomes. Together, nucleosomes and DNA form chromatin, which is the primary substance of chromosomes. This DNA-packaging system is vital for managing development and maintaining health. When it goes awry, cancer can be the result.
In a study published in Molecular Cell this month, Alexei V. Tulin, PhD, Associate Professor at Fox Chase Cancer Center, and colleagues reported that chemical modification of one type of histone—called H2Av—leads to substantial changes in nucleosome shape. As a consequence, a previously hidden portion of the nucleosome becomes exposed. This newly exposed portion interacts with and activates an enzyme called PARP1. Upon activation, PARP1 assembles long branching molecules of Poly(ADP-ribose), which appear to open the DNA packaging around the site of the PARP1 activation, exposing specific genes for activation.
“Currently, the nucleosome is often portrayed as a stable, inert structure, or a tiny ball,” Tulin says. “We found that the nucleosome is actually a quite dynamic structure. When we modified one histone, we changed the whole nucleosome.”
In addition to reevaluating how histones control gene activation, the study also reports a new mechanism of PARP1 regulation. Many standard cancer treatments, including chemotherapy drugs and radiation therapy, damage the DNA of rapidly dividing cancer cells. However, the effectiveness of these treatments is limited. Research has suggested that standard therapies combined with drugs that inhibit PARP1 can kill cancer cells, but clinical trials testing PARP1 inhibitors in cancer patients have produced disappointing outcomes. “I believe that to a large extent the previous setbacks were caused by a general misconception of the role of PARP1 in living cells and the mechanisms of PARP1 regulation,” Tulin says. “Now that we know this mechanism of PARP1 regulation, we can design approaches to inhibit this protein in an effective way to better treat cancer.”
The ability of PARP1 to control cellular processes is regulated by nucleosomes—the basic unit of DNA packaging, consisting of a segment of DNA wound in sequence around eight histone protein cores, similar to a thread wrapped around a spool. Histones undergo different chemical modifications that play an important role in regulating the activity of genes. Through this mechanism, histones control the ability of PARP1 to activate genes and repair DNA damage.
“This mechanism of PARP1 regulation by histones is still very new,” Tulin says. “People believe that PARP1 is mainly activated through interactions with DNA, but we have found that the main pathway of PARP1 activation is through interactions with the nucleosome.” In the new study, Tulin and his colleagues reevaluated how PARP1 is activated by changes in the nucleosome. They found that the addition of a phosphate group to a histone—called H2Av—triggered the entire nucleosome to change shape, exposing previously hidden parts of the nucleosome that began to interact with and activate PARP1.
To follow up on these findings, Tulin and his team are now developing the next generation of PARP1 inhibitors. Designed to block the newly identified mechanism of PARP1 activation, these new inhibitors will specifically target PARP1, in contrast to the PARP1 inhibitors currently being tested in clinical trials.
“We expect that our targeted PARP1 inhibitors will be more effective at killing cancer cells while protecting important molecular pathways in normal cells,” Tulin says. “For this reason, we believe that the specific inhibitors we are designing hold great promise for cancer treatment.”
Co-investigators on the study include Colin J. Thomas, Elena Kotova, Mark Andrake, and Jared Adolf-Bryfogle of Fox Chase; Robert Glaser of the New York State Department of Health in Albany; and Catherine Regnard of Ludwig Maximilian University in Munich, Germany. This research was supported by grants from the National Institutes of Health (R01 GM077452 and R01 DK082623) to Tulin.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Diana Quattrone | EurekAlert!
New Model of T Cell Activation
27.05.2016 | Albert-Ludwigs-Universität Freiburg im Breisgau
Fungi – a promising source of chemical diversity
27.05.2016 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie - Hans-Knöll-Institut (HKI)
A biological and energy-efficient process, developed and patented by the University of Innsbruck, converts nitrogen compounds in wastewater treatment facilities into harmless atmospheric nitrogen gas. This innovative technology is now being refined and marketed jointly with the United States’ DC Water and Sewer Authority (DC Water). The largest DEMON®-system in a wastewater treatment plant is currently being built in Washington, DC.
The DEMON®-system was developed and patented by the University of Innsbruck 11 years ago. Today this successful technology has been implemented in about 70...
Permanent magnets are very important for technologies of the future like electromobility and renewable energy, and rare earth elements (REE) are necessary for their manufacture. The Fraunhofer Institute for Mechanics of Materials IWM in Freiburg, Germany, has now succeeded in identifying promising approaches and materials for new permanent magnets through use of an in-house simulation process based on high-throughput screening (HTS). The team was able to improve magnetic properties this way and at the same time replaced REE with elements that are less expensive and readily available. The results were published in the online technical journal “Scientific Reports”.
The starting point for IWM researchers Wolfgang Körner, Georg Krugel, and Christian Elsässer was a neodymium-iron-nitrogen compound based on a type of...
In the Beyond EUV project, the Fraunhofer Institutes for Laser Technology ILT in Aachen and for Applied Optics and Precision Engineering IOF in Jena are developing key technologies for the manufacture of a new generation of microchips using EUV radiation at a wavelength of 6.7 nm. The resulting structures are barely thicker than single atoms, and they make it possible to produce extremely integrated circuits for such items as wearables or mind-controlled prosthetic limbs.
In 1965 Gordon Moore formulated the law that came to be named after him, which states that the complexity of integrated circuits doubles every one to two...
Characterization of high-quality material reveals important details relevant to next generation nanoelectronic devices
Quantum mechanics is the field of physics governing the behavior of things on atomic scales, where things work very differently from our everyday world.
When current comes in discrete packages: Viennese scientists unravel the quantum properties of the carbon material graphene
In 2010 the Nobel Prize in physics was awarded for the discovery of the exceptional material graphene, which consists of a single layer of carbon atoms...
24.05.2016 | Event News
20.05.2016 | Event News
19.05.2016 | Event News
30.05.2016 | Materials Sciences
30.05.2016 | Materials Sciences
30.05.2016 | Trade Fair News